R
esearch reported in 2011 from several American and European universities supports the decades-old hypothesis that people with allergies have a low incidence of glioma: up to four times lower than that of non-allergy sufferers in some studies.
First identifi ed two decades ago, the inverse relationship between allergies and glioma "is one of the most consistent associations in the brain tumor literature," wrote Darrell Bigner, M.D., Ph.D., director of the Duke University Tisch Brain Tumor Center, in a February 2011 Cancer Epidemiology paper.
Although past studies have failed to confi rm the inverse allergy association in meningioma and acoustic neuroma, they have confi rmed it for glial cells.
The most recent study, published in the Oct. 18 JNCI , found a statistically significant inverse association between glioma and borderline-elevated total immunoglobulin E (IgE), a biomarker often found in allergy sufferers. Healthy participants from four cohorts contributed blood samples well before brain tumors developed, suggesting that any chemotherapy-or tumorinduced immune alterations "were unlikely to cause the observed changes in IgE," N E W S observation that could unlock a lot of important clinical science."
Solving a Mystery
Clinical relevance is most likely to emerge, experts say, from the mechanism by which allergies reduce glioma incidence if the inverse association is indeed causal, a mystery that virtually every study touches on. The idea that the same hypervigilant immune surveillance that causes allergies may also quash tumor cells is the leading contender among suggested mechanisms. But that idea falls short, experts say, mainly because the blood -brain barrier renders immune mechanisms not altogether inactive but, rather, muted in the brain.
A better explanation may be the prophylaxis, or toxin, hypothesis, said Cornell University neurobiology professor Paul Sherman, Ph.D., who in a December 2008 Quarterly Review of Biology paper applied the concept to every study on allergies and cancer since 1953. Proposed by University of California, Berkeley, evolutionary biologist Margie Profet in a 1991 Quarterly Review of Biology paper, the prophylaxis hypothesis asserts that allergies evolved through Darwinian natural selection as a "last line of defense" against carcinogens and mutagens.
"The IgE system and associated allergy symptoms may serve a common protective mechanism: the rapid expulsion of pathogens, dangerous natural toxins, and carcinogenic antigens before they can trigger malignant neoplasm," wrote Cornell University evolutionary biologist and team member Janet Shellman-Sherman, Ph.D., applying the prophylaxis argument to cancer. The Sherman study is the only study to date of any potential mechanisms behind the allergy -cancer relationship.
Allergy symptoms such as coughing, sneezing, and diarrhea physically expel carcinogens from the body, Profet argued. Biochemically, IgE antibodies "target the specifi c molecular confi gurations of mutagens and carcinogens that have evaded general defense mechanisms."
Decreases in blood pressure that accompany anaphylactic shock, bronchial constriction, and swollen sinuses play a related role, Profet claimed, reducing or blocking an allergenic toxin ' s ability to circulate.
Her paper even suggests that allergenicity is a measure of carcinogenicity. The four most carcinogenic metals -arsenic, beryllium, chromium, and nickel -are also the most allergenic, Profet notes, and allergens such as Birch pollen and Brazil nuts contain potent carcinogens such as caffeic acid, sesquiterpene lactones, and nickel.
The idea that allergenicity and carcinogenicity are related emerged after Profet and UC-Berkeley toxicologist Bruce Ames, Ph.D., used the Ames test -a measure of carcinogenicity -to identify hundreds of naturally occurring carcinogens, many also allergenic. Some surprising examples include isothiocyanate in cabbage, 8-methoxysporalen in celery, and safrole in black pepper and nutmeg. Afl atoxin in mold is an example of a carcinogen found as a contaminant in some foods. "Natural and synthetic chemicals are equally likely to be positive for carcinogenicity in animal cancer tests," Ames concluded. And Profet wrote, "The possibility that allergy evolved to defend against toxins has been overlooked, and the toxicity of most allergens has not been appreciated."
From Cases to Cohorts
A team led by Harvard Medical School associ ate neurology profes sor Fred Hochberg, M.D., fi rst identifi ed an inverse relationship between glioma and allergy. In a 1990 Journal of Neuro-Oncology study of 160 glioblastoma and astrocytoma patients, they examined allergies, family history of central nervous system malignancies, cranial irradiation, cigarette smoking, alcohol consumption, drug use, and intake of cured or smoked foods. Comparing with 128 healthy control subjects, the researchers reported "evidence that glioblastoma is associated with a decreased susceptibility to allergies" but was unrelated to the other factors.
Papers followed from case -control studies in the U.S., Sweden, the UK, Germany, Norway, Finland, and Denmark with the same essential fi nding: "a significant inverse association between glioma and history of allergies," as a seven-member team led by National Cancer Institute radiation epidemiologist Alina Brenner, Ph. 
N E W S
is a true observation not based on any sort of bias," he explained.
Finally, several studies have shown that the inverse association is dose dependent. The risk of developing glioma decreased 31% -45% with each additional allergy, a team led by Duke University Comprehensive Cancer Center epidemiologist Dora Il ' yasova, Ph.D., reported in a 2009 Cancer Epidemiology, Biomarkers, and Prevention paper. If hay fever reduces glioma risk by half, for instance, hay fever plus cat dander allergy might reduce it by 60%; hay fever plus cat allergy plus an allergy to Brazil nuts by 80%; and so forth.
The biggest questions remain about the risk-reduction mechanism, which "is thought to be elimination of procancerous cells by increased immunosurveillance," Il ' yasova reported.
Consistent with the fi ndings of past research, these tissues include gray matter but exclude the meninges. Eight studies since 2002 have shown that ultrafi ne airborne particles, viruses, and drugs deposited on nasal mucosa rapidly traverse the blood -brain barrier via the olfactory nerve and nasal epithelium -except when sinuses are allergically swollen, Cornell ' s Sherman explained.
People with severe allergies also have lower concentrations of environmental carcinogens in their blood, a fi nding consistent with the prophylaxis argument, Sherman said. A 2002 Belgian case -control study found high IgE levels statistically correlating with low dioxin-like hydrocarbons, and a 2006 Western Australia population study found inverse correlations between circulating allergy-associated cytokines and PCB (polychlorinated biphenyl), organochlorine pesticides, and dichloroethylene.
Despite the epidemiological evidence, Wiemels said he fi nds the prophylaxis hypothesis "interesting" but doesn ' t see allergy ' s evolutionary benefi ts.
The heightened immune-surveillance mechanism makes better sense to Michael Schulder. First recognized at the cellular level as "nonself" and rapidly destroyed by the immune system, a nascent glioma would never become clinically or pathologically apparent, giving the appearance of allergyrelated prevention, Schulder explained.
"Immunity -cancer discussions like this have been going on for decades," he said. "Does an immune mechanism exist? Can it be stimulated? We still don ' t know."
The Allergist -Oncologist
With a global task force, annual symposium, and textbook coedited by University of Vienna pathophysiology professor Erika Jensen-Jarolim, M.D., and UCLA Geffen School of Medicine surgery and immunology professor Manuel Penichet, M.D., Ph.D., "allergo-oncology" is a burgeoning fi eld, but without an as yet clear, clinical purpose.
To change that, allergo-oncology research needs to move into the laboratory, Ohio State ' s Schwartzbaum said. "You can ' t make inferences from observational studies alone," she explained. "We still need laboratory work after the epidemiology results come in." Given glioma ' s rare incidence, "we also need larger cohorts," she added. "My cohort results and others are based on relatively small sample sizes."
Long-term use of the newer drug omalizumab (Xolair), which blocks all IgEmediated allergy symptoms, should offer new opportunities for more cohort studies, Sherman explained. "People who cannot mount allergy symptoms should be more at risk for cancers such as glioma."
Given the lack of other consistent relationships between environmental factors and glioma risk, Schulder hopes that continued population studies, both case -control and cohort, will encourage clinical research. "Epidemiology often leads to clinical relevance, a good example being the link between cancer and smoking," he said.
In all, the need for larger cohorts, reproducible laboratory fi ndings, and that important missing mechanism leave the allergy -glioma question unresolved, Brown ' s Michaud explained. "Studies such as ours and others may point to new etiologies," he said. "But we are far from understanding what causes glioma."
